Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11804
Peer-review started: August 1, 2022
First decision: August 21, 2022
Revised: September 8, 2022
Accepted: October 19, 2022
Article in press: October 19, 2022
Published online: November 16, 2022
The effects of T-cell immunoglobulin mucin molecule-3 (Tim-3), transforming growth factor β (TGF-β), and chemokine-12 (CXCL12) expression on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) have not been elucidated.
To examine the correlation between Tim-3, TGF-β and CXCL12 expression and DLBCL prognosis.
Lymph node tissues of 97 patients with DLBCL and 93 normal-response hype
The positive expression rates of Tim-3, TGF-β, and CXCL12 were higher in DLBCL tissues than in non-cancerous (control) tissues (P < 0.05). One-year post-surgery, the positive expression rates of Tim-3, TGF-β, and CXCL12 were higher in patients with effective treatment than in those with ineffective treatment (P < 0.05). The 3-year progression-free survival of 97 patients with DLBCL was 67.01% (65/97). Univariate analysis revealed that clinical stage, bone marrow infiltration, International Prognostic Index (IPI) score, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were associated with poor prognosis (P < 0.05). Multivariate Cox regression analysis demonstrated that clinical stage III–IV, bone marrow infiltration, mediate-to-high-risk IPI scores, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were independent risk factors affecting prognosis (P < 0.05).
DLBCL tissues exhibit high positive expression of Tim-3, TGF-β, and CXCL12, and a high expression of all three indicates a poor prognosis.
Core Tip: Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor with a poor prognosis. T-cell immunoglobulin mucin molecule-3 (Tim-3), transforming growth factor β (TGF-β), and chemokine 12 (CXCL12) can affect the prognosis of solid tumors by participating in the tumor immune escape. Therefore, we analyzed the effects of Tim-3, TGF-β, and CXCL12 expression on DLBCL prognosis. The results suggest that Tim-3 positive, TGF-β positive, and CXCL12 positive are independent risk factors; therefore, they can be used to evaluate the efficacy and prognosis of DLBCL patients.